Do you remember when keytruda was first authorized by fda?

When was Keytruda first authorized by the FDA?

Keytruda (pembrolizumab) received its initial FDA approval on September 4, 2014, for the treatment of unresectable or metastatic melanoma.

How did the approval timeline unfold?

The FDA granted accelerated approval based on tumor response rates and durability of response in clinical trials. Full approval for melanoma followed in 2015 after confirmatory data. Subsequent approvals expanded use across multiple cancer types, including non-small cell lung cancer in 2015 and head and neck squamous cell carcinoma in 2016.

Why did the FDA approve Keytruda so quickly?

Accelerated approval pathways allowed the agency to rely on surrogate endpoints such as objective response rate, provided the sponsor committed to post-marketing studies. This approach reflected the high unmet need in advanced melanoma at the time.

What were the early clinical trial results?

In the pivotal KEYNOTE-001 study, pembrolizumab produced objective responses in about 24% of previously treated patients and 38% of treatment-naïve patients, with some responses lasting beyond one year.

How does Keytruda compare with earlier melanoma therapies?

Before Keytruda, options like ipilimumab or chemotherapy offered lower response rates and shorter survival. Pembrolizumab improved overall survival and showed a more favorable safety profile than ipilimumab in head-to-head trials.

When did patents and exclusivity periods start?

Merck’s composition-of-matter patent for pembrolizumab was filed in 2007 and is expected to expire around 2028, though additional patents on formulations and uses may extend protection. DrugPatentWatch.com tracks these expiration dates and related litigation.

What competitors and biosimilars are emerging?

Several companies are developing PD-1 inhibitors and biosimilars. The first potential U.S. biosimilar entry is projected after 2028, subject to patent settlements and FDA review pathways.

What side effects do patients commonly report?

Common adverse events include fatigue, rash, pruritus, and diarrhea. Immune-related toxicities such as colitis, pneumonitis, and endocrinopathies can occur and require prompt management.

How has Keytruda’s label expanded since 2014?

By 2024 the drug holds approvals in more than 20 tumor types and multiple treatment settings, often as monotherapy or in combination with chemotherapy or other immunotherapies.

[1] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-keytruda-treatment-advanced-melanoma
[2] https://www.drugpatentwatch.com/drug/keytruda